

July 3, 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Lilly wows ADA with obesity results; Novo's oral semaglutide data; first DMD gene therapy approved; the outlook for biopharma fundraising; and Korean pharma considers strategy in a changing world.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended June 30, 2023, including: [Eli Lilly and Company](#) wows ADA with obesity results; [Novo Nordisk A/S](#)'s oral semaglutide data; first DMD gene therapy approved; the outlook for biopharma fundraising; and Korean pharma considers strategy in a changing world.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Lilly Wows ADA Crowd With Obesity Data Across Three-Drug Incretin Portfolio](#)" - Scrip, June 26, 2023.)

(Also see "[With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA](#)" - Scrip, June 25, 2023.)

(Also see "[A Momentous Day For DMD: Sarepta's Elevidys Is First Gene Therapy Approved](#)" - Scrip, June 22, 2023.)

(Also see "[Biopharma Investors, Companies Learning To Adjust To Financial Market Realities](#)" - Scrip, June 27, 2023.)

(Also see "[Survive Or Fall: Korean Strategy In Changing Big Pharma Environment](#)" - Scrip, June 27, 2023.)

[Click here to explore this interactive content online](#) ✎